The estimated Net Worth of Teresa De Luca is at least $2.47 Millón dollars as of 21 November 2022. Teresa Luca owns over 20,000 units of Surgery Partners Inc stock worth over $1,460,626 and over the last 8 years he sold SGRY stock worth over $793,783. In addition, he makes $215,000 as Independent Director at Surgery Partners Inc.
Teresa has made over 11 trades of the Surgery Partners Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of SGRY stock worth $490,000 on 21 November 2022.
The largest trade he's ever made was buying 20,000 units of Surgery Partners Inc stock on 21 November 2022 worth over $490,000. On average, Teresa trades about 2,332 units every 59 days since 2016. As of 21 November 2022 he still owns at least 47,968 units of Surgery Partners Inc stock.
You can see the complete history of Teresa Luca stock trades at the bottom of the page.
Dr. Teresa DeLuca M.D. serves as Independent Director of the Company. Dr. DeLuca has served as a Managing Director at Columbia University's NY Life Science Venture Fund since January 2018. She previously served as Assistant Clinical professor of psychiatry at the Icahn School of Medicine at Mount Sinai in New York City from 2014 to 2017 and as the Chief Medical Officer of Magellan Pharmacy Solutions at Magellan Health from 2012 to 2014. Prior to that, she served as SVP of Pharmacy Health Solutions at Humana, VP of Clinical Sales Solutions & National Medical Director at Walgreen Co., and VP of Personalized Medicine as well as VP of Medical Policy & Clinical Quality at Medco. Prior to taking on these executive leadership roles, Dr. DeLuca was a Senior Director of Global Product Development Services at PRA International and a Senior Medical Scientist at GlaxoSmithKline. Dr. DeLuca served as a director at North Bud Farms, Inc., a pharmaceutical company from May 2018 to February 2020. Dr. DeLuca received her M.B.A. from Drexel University and her residency (M.D.) from Jefferson Medical College of Thomas Jefferson University. Our Board believes that Dr. DeLuca is qualified to serve as a director based on, among other things, her healthcare knowledge, experience and skills gained from previously serving as a Chief Medical Officer. Additionally, a strong advocate for good board governance, in 2016 Dr. DeLuca earned both the Carnegie Mellon Cybersecurity certificate and continues to maintain good standing with the National Association of Corporate Directors (NACD) as a Board Leadership Fellow (Masters Level).
As the Independent Director of Surgery Partners Inc, the total compensation of Teresa DeLuca at Surgery Partners Inc is $215,000. There are 12 executives at Surgery Partners Inc getting paid more, with J. Eric Evans having the highest compensation of $4,644,930.
Teresa DeLuca is 54, he's been the Independent Director of Surgery Partners Inc since 2018. There are 5 older and 14 younger executives at Surgery Partners Inc. The oldest executive at Surgery Partners Inc is Clifford Adlerz, 66, who is the Director.
Teresa's mailing address filed with the SEC is C/O SURGERY PARTNERS, INC., 340 SEVEN SPRINGS WAY, SUITE 600, BRENTWOOD, TN, 37027.
Over the last 9 years, insiders at Surgery Partners Inc have traded over $1,643,866,633 worth of Surgery Partners Inc stock and bought 83,000 units worth $1,133,800 . The most active insiders traders include T. Devin O'reilly, Surgery Centers, Llchig Gp ... y Capital Investors Llcbcpe S.... On average, Surgery Partners Inc executives and independent directors trade stock every 26 days with the average trade being worth of $26,258,040. The most recent stock trade was executed by Harrison R. Bane on 1 September 2024, trading 6,325 units of SGRY stock currently worth $196,771.
surgery partners is a leading operator of surgical facilities and ancillary services with more than 180 locations nationwide. we provide exceptional integrated healthcare experiences between our providers and patients. our diverse company operates multiple types of healthcare services dedicated to improving the quality of care in a convenient and cost-effective manner. the support of our ancillary services is one of many unique attributes that differentiate us from our competitors. these services are comprised of a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, anesthesia services, optical services and specialty pharmacy services. our integrated approach to advancing markets allows for flexibility to provide care on an individualized, local market basis. whether entering into a new market with surgical facilities, ancillary services or joint ventures with health systems, or furthering an existing market’s growth potential by focusing on base busines
Surgery Partners Inc executives and other stock owners filed with the SEC include: